NESS ZIONA, Israel, August 24 /PRNewswire/ -- Foamix Ltd., a leading developer of topical foams for dermatology and gynecology, announced today that it has been awarded US Patent #7575739 pertaining to its foam technology. The patent covers unique foam compositions, suitable for the treatment of heat and chemical burns, wounds, bacterial, fungal and viral infections.
Dr. Dov Tamarkin, the Company's CEO stated, "The novelty of our foam technology platform is that it enables facile delivery of active agents to the inflicted site. Our foams are breakable - they are easily applied to the sensitive area of wounds and burns and they are absorbed readily into the treated area."
Foamix expends significant resources on protecting its intellectual property. To date, Foamix has five issued U.S. patents covering its OilGel(TM) and topical foam technology platforms. An additional 70 U.S. patent applications, protecting its proprietary foam platforms are under prosecution, covering compositions, applications, methods of use and delivery devices. The Company employs leading U.S. patent counsel (Wilmer Hale, Boston) as well as an in-house intellectual property team.
Headquartered in Ness Ziona, Israel, Foamix Ltd. is a leading developer of topical foams for dermatology and gynecology. Foamix's state-of-the-art foams provide controlled delivery of a variety of active ingredients. Foamix is currently collaborating with 10 pharmaceutical and cosmetic companies on 12 projects in the development of proprietary dermatological and gynecologic foam drugs. Additionally, the Company has an extensive in-house pipeline of dermatological and gynecological drugs in foam presentation.
Foamix holds 5 US patents and has 70 patents pending in the United States.
For additional information please visit http://www.foamix.co.il
Press inquiries: Sigal Maymon, Foamix Ltd, +972-8-9316233 or email@example.com
|SOURCE Foamix Ltd|
Copyright©2009 PR Newswire.
All rights reserved